People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Reprieve Cardiovascular, Inc. | — | Other Health Care | Series B | $82.4M | $153.0M | 2023 |
Jan S. Garfinkle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jan S. Garfinkle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hanson S. Gifford III | 1 | 11 |
| Gregory W. Mann | 1 | 2 |
| Mark Pacyna | 1 | 2 |
| Andrew S. ElBardissi | 1 | 2 |
| Tony Fields | 1 | 2 |
| Adam S. Bartnik | 1 | 1 |
| David S. Neustaedter | 1 | 1 |
| Mark W. Pacyna | 1 | 1 |
| Jim S. Dillon | 1 | 1 |
| Tony S. Fields | 1 | 1 |
| Mark S. Pacyna | 1 | 1 |
| Ethan S. Benovitz | 1 | 1 |
| James S. Eadie | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.